Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • News
    • News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
  • Toggle search form

[Disclosure] Celltrion (068270) Decides to Buy Back KRW 100B Worth of Common Shares to Stabilize Stock Price

Posted on July 21, 2025July 15, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Decides to Buy Back KRW 100B Worth of Common Shares to Stabilize Stock Price

Source Fact: Financial Supervisory Service DART / 2025-07-21

Disclosure Type: Report on Major Corporate Decisions (Decision on Share Buyback)

💡 3-Second Summary

Celltrion has decided to purchase 554,632 common shares directly on the market for approximately KRW 100 billion to stabilize its stock price and enhance shareholder value.

📊 1. [Key Disclosure Details & Major Figures]

  • Estimated Number of Shares to Acquire: 554,632 Common Shares
  • Estimated Acquisition Amount: KRW 100,000,149,600 (Approx. KRW 100B)
    • Based on the closing price of KRW 180,300 on July 18, 2025 (the day prior to the Board of Directors’ decision date). The actual acquisition amount may change depending on stock price fluctuations.
  • Expected Acquisition Period: July 22, 2025 ~ October 21, 2025 (Expected holding period is at least 6 months from the final acquisition date)
  • Purpose of Acquisition: Stock price stabilization and enhancement of shareholder value
  • Method of Acquisition: Direct on-market purchase through the KRX (KOSPI) market
  • Entrusted Investment Brokers: NH Investment & Securities, Meritz Securities
  • Daily Purchase Limit: 126,081 Common Shares
  • Treasury Share Status Prior to Current Buyback:
    • Acquired within the distributable profit limit: 6,040,434 shares (2.6%)
    • Other acquisitions: 5,182,369 shares (2.2%)
    • Total: 11,222,803 shares

📈 2. [Expert Perspective: What This Means for Investors]

This announcement reflects Celltrion’s corporate action to utilize its internal funds to purchase its own shares directly from the open market to boost shareholder returns. A buyback worth approximately KRW 100 billion is highly likely to act as a solid shock absorber for the stock price in the short term, as it introduces a reliable, large-scale buyer to the market. With a daily purchase limit of 126,081 shares, a consistent influx of buying demand is anticipated over the designated three-month buyback period.

From a financial health perspective, this decision is highly sustainable. Celltrion’s legally permissible limit for share buybacks (based on the commercial law’s distributable profit limit) stands at an ample KRW 4.38T (trillion). Thus, executing a buyback of KRW 100B (billion) represents a low-risk capital allocation that does not strain the company’s financial structure. However, unless these purchased treasury shares are permanently cancelled (retired), the long-term impact on boosting earnings per share (EPS) might be limited, as they merely reduce floating supply temporarily.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion’s decision to buy back its own shares once again confirms the management’s strong commitment to active defensive maneuvers during periods of market uncertainty. This move sends a clear signal to market participants that the current stock price is perceived by the company as undervalued compared to its intrinsic corporate value.

Going forward, global investors should focus on two key variables. First is whether this buyback will eventually lead to actual “share retirement.” Treasury shares that are simply held on the balance sheet can always be re-introduced to the market in the future, meaning they represent a potential overhang risk unless they are permanently deleted.

Second is the actual pace and execution of the daily buybacks during the designated period (July 22 – October 21). While these open-market purchases serve as a temporary downside cushion for the stock price, the true driver for sustainable mid-to-long-term valuation will remain the fundamentals of the company’s core business—specifically, its new biosimilar approvals and global sales growth.

📢 Disclaimer & Source

Source: This content has been structured and rewritten based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.

Inquiries: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Minority Shareholders File Injunction to Suspend Hana Micron’s (067310) Corporate Split Resolution; Legal Battle Over Governance Begins
Next Post: [Disclosure] Celltrion (068270) Reports Q2 Preliminary Operating Profit of KRW 242.5B, Up 234.49% YoY

Related Posts

[Disclosure] Hanwha Ocean (042660) Announces Investor Relations (IR) Event for Q2 2025 Earnings Release Disclosures
[Disclosure] SK hynix Inc. (000660) Officially Decides on U.S. Nasdaq Listing—Issuing 17.79M New Shares for Global ADR Offering Semiconductors
[Disclosure] Hanwha Aerospace (012450) Signs Amended Contract for ‘CBRN Reconnaissance Vehicle-II (Wheeled) Follow-up Production and 53 Other Items’ with DAPA Disclosures
[Disclosure] Hanwha Ocean (042660) to Hold Investor Relations (IR) Meetings in Singapore and Hong Kong for Foreign Institutional Investors Disclosures
[Disclosure] Hanwha Aerospace (012450) Announces Expiration of Mandatory Retention (Lock-up) Period for 1.71M Common Shares Issued via Third-Party Placement Disclosures
[Disclosure] Hanwha Ocean (042660) Decides KRW 332.8B New Facilities Investment for Floating Dock Expansion to Increase Production Volume Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Alteogen (196170) Establishes August 6 as Record Date for Bonus Issue Share AllotmentJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Trading Suspension and Resumption Schedule for Stock Futures and OptionsJuly 16, 2026
  • [Disclosure] Alteogen (196170) Temporarily Suspends Plans for Relisting on the KOSPI MarketJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Temporary Trading Suspension on July 16 Due to Bonus Issue DecisionJuly 16, 2026
  • [Disclosure] Alteogen (196170) Decides on Bonus Issue of 0.3 Shares per 1 Common and Preferred ShareJuly 16, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme